{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:39:35Z","timestamp":1785368375226,"version":"3.55.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T00:00:00Z","timestamp":1657929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T00:00:00Z","timestamp":1657929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003995","name":"Natural Science Foundation of Anhui Province","doi-asserted-by":"publisher","award":["No.2008085QH408"],"award-info":[{"award-number":["No.2008085QH408"]}],"id":[{"id":"10.13039\/501100003995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81874063"],"award-info":[{"award-number":["No.81874063"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Causative factors of breast cancer include infections, such as Epstein\u2013Barr virus (EBV) infection. The aim of this study was to analyze the clinicopathological features of EBV-positive (IBC) and determine if EBV affects programmed cell death receptor 1 (PD-1)\/PD ligand 1 (PD-L1) expression in IBC, similar to other EBV-infected tumors with PD-L1\/PD-1 expression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We collected 140 samples of IBC tissues and 25 samples of adjacent tissues. All patients were followed-up by telephone from the day of surgery to December 2020. Chromogenic in-situ hybridization was performed to evaluate EBV-encoded RNA (EBER). Immunohistochemistry was performed to evaluate PD-L1 and PD-1 expressions. The correlation between PD1\/PDL1 expression and clinicopathological features was also analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>EBER was detected in 57 of 140 (40.7%) IBC tissues and not detected in any adjacent tissue (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Clinicopathologic features of patients were consistent with EBV-associated IBC. EBV infection was correlated with the mass size, menopausal status, axillary lymph node metastasis, vascular invasion, Ki-67 index, clinical stage, and estrogen receptor and progesterone receptor expressions (all <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), but not with the histological type, invasive ductal carcinoma histological grade, or human epidermal growth factor receptor 2 (HER2) expression (all <jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05). The positive rate of PD-1\/PD-L1 expression was higher in the EBV-positive group than in the EBV-negative group (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). The Kaplan\u2013Meier univariate survival analysis showed that EBV was associated with poor disease-free survival and overall survival in patients with IBC. PD-L1\/PD-1 expression could predict a poor prognosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In this study, clinicopathologic characteristics of patients were consistent with EBV-infected IBC. Patients with EBV-positive breast cancer were more likely to have elevated PD-1\/PDL-1 expression compared to those with EBV-negative breast cancer. This finding could serve as a basis to explore therapeutic targets, particularly immunotherapy, for patients with IBC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13000-022-01234-3","type":"journal-article","created":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T06:02:41Z","timestamp":1657951361000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Association of PD-1\/PD-L1 expression and Epstein-\u2013Barr virus infection in patients with invasive breast cancer"],"prefix":"10.1186","volume":"17","author":[{"given":"Wei-tong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-lu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu-qin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-xiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,16]]},"reference":[{"issue":"6","key":"1234_CR1","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.7314\/apjcp.2012.13.6.2577","volume":"13","author":"BL Han","year":"2012","unstructured":"Han BL, Xu XY, Zhang CZ, et al. Systematic review on Epstein-Barr virus (EBV) DNA in diagnosis of nasopharyngeal carcinoma in Asian populations. Asian Pac J Cancer Prev. 2012;13(6):2577\u201381. https:\/\/doi.org\/10.7314\/apjcp.2012.13.6.2577.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"1","key":"1234_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-011-1921-4","volume":"135","author":"D Joshi","year":"2012","unstructured":"Joshi D, Buehring GC. Are viruses associated with human breast cancer? Scrutinizing the molecular evidence. Breast Cancer Res Treat. 2012;135(1):1\u201315. https:\/\/doi.org\/10.1007\/s10549-011-1921-4.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"1234_CR3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1158\/1541-7786.MCR-16-0305","volume":"15","author":"Y Kaymaz","year":"2017","unstructured":"Kaymaz Y, Oduor CI, Yu H, et al. Comprehensive Transcriptome and mutational profiling of endemic Burkitt lymphoma reveals EBV type-specific differences. Mol Cancer Res. 2017;15(5):563\u201376. https:\/\/doi.org\/10.1158\/1541-7786.MCR-16-0305.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"1234_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41698-021-00162-7","volume":"5","author":"C Smith","year":"2021","unstructured":"Smith C, Mcgrath M, Neller MA, et al. Complete response to PD-1 blockade following EBV-specific T-cell therapy in metastatic nasopharyngeal carcinoma. NPJ Precis Oncol. 2021;5(1):24. https:\/\/doi.org\/10.1038\/s41698-021-00162-7.","journal-title":"NPJ Precis Oncol"},{"issue":"3","key":"1234_CR5","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.3892\/mmr.2019.9886","volume":"19","author":"H Zhou","year":"2019","unstructured":"Zhou H, Tan S, Li H, et al. Expression and significance of EBV, ARID1A and PIK3CA in gastric carcinoma. Mol Med Rep. 2019;19(3):2125\u201336. https:\/\/doi.org\/10.3892\/mmr.2019.9886.","journal-title":"Mol Med Rep"},{"issue":"1","key":"1234_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1749-6632.1995.tb12155.x","volume":"55","author":"LG Labrecque","year":"1995","unstructured":"Labrecque LG, Barnes DM, Fentiman IS, et al. Epstein-Barr virus in epithelial cell tumors: a breast cancer study. Cancer Res. 1995;55(1):39\u201345. https:\/\/doi.org\/10.1111\/j.1749-6632.1995.tb12155.x.","journal-title":"Cancer Res"},{"issue":"12","key":"1234_CR7","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","volume":"5","author":"H Dong","year":"1999","unstructured":"Dong H, Zhu G, Tamada K, et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5(12):1365\u20139. https:\/\/doi.org\/10.1038\/70932.","journal-title":"Nat Med"},{"issue":"1","key":"1234_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-016-0277-y","volume":"9","author":"W Ma","year":"2016","unstructured":"Ma W, Gilligan BM, Yuan J, et al. Current status and perspectives in translational biomarker research for PD-1\/PD-L1 immune checkpoint blockade therapy. J Hematol Oncol. 2016;9(1):47. https:\/\/doi.org\/10.1186\/s13045-016-0277-y.","journal-title":"J Hematol Oncol"},{"issue":"11","key":"1234_CR9","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s12094-021-02657-y","volume":"23","author":"MA Gamaleldin","year":"2021","unstructured":"Gamaleldin MA, Ghallab OM, Nadwan EA, et al. PD-1 and PD-L1 gene expressions and their association with Epstein-Barr virus infection in chronic lymphocytic leukemia. Clin Transl Oncol. 2021;23(11):2309\u201322. https:\/\/doi.org\/10.1007\/s12094-021-02657-y.","journal-title":"Clin Transl Oncol"},{"key":"1234_CR10","doi-asserted-by":"publisher","first-page":"107553","DOI":"10.1016\/j.intimp.2021.107553","volume":"95","author":"X Li","year":"2021","unstructured":"Li X, Zhang W. Expression of PD-L1 in EBV-associated malignancies. Int Immunopharmacol. 2021;95:107553. https:\/\/doi.org\/10.1016\/j.intimp.2021.107553.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1234_CR11","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1038\/s41598-021-81667-w","volume":"11","author":"H Nakano","year":"2021","unstructured":"Nakano H, Saito M, Nakajima S, et al. PD-L1 overexpression in EBV-positive gastric cancer is caused by unique genomic or epigenomic mechanisms. Sci Rep. 2021;11(1):1982. https:\/\/doi.org\/10.1038\/s41598-021-81667-w.","journal-title":"Sci Rep"},{"issue":"3","key":"1234_CR12","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s10120-018-0880-4","volume":"22","author":"S Sasaki","year":"2019","unstructured":"Sasaki S, Nishikawa J, Sakai K, et al. EBV-associated gastric cancer evades T-cell immunity by PD-1\/PD-L1 interactions. Gastric Cancer. 2019;22(3):486\u201396. https:\/\/doi.org\/10.1007\/s10120-018-0880-4.","journal-title":"Gastric Cancer"},{"key":"1234_CR13","doi-asserted-by":"publisher","unstructured":"Tan P, Ellis I, Allison K, et al. The 2019 WHO classification of tumours of the breast. Histopathology. 2020;77. https:\/\/doi.org\/10.1111\/his.14091.","DOI":"10.1111\/his.14091"},{"issue":"14","key":"1234_CR14","doi-asserted-by":"publisher","first-page":"8418","DOI":"10.1073\/pnas.0932692100","volume":"100","author":"T Sorlie","year":"2003","unstructured":"Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418\u201323. https:\/\/doi.org\/10.1073\/pnas.0932692100.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"1234_CR15","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/jnci\/djab004","volume":"113","author":"LA Emens","year":"2021","unstructured":"Emens LA, Molinero L, Loi S, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast Cancer: biomarker evaluation of the IMpassion130 study. J Natl Cancer Inst. 2021;113(8):1005\u201316. https:\/\/doi.org\/10.1093\/jnci\/djab004.","journal-title":"J Natl Cancer Inst"},{"issue":"19","key":"1234_CR16","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","volume":"20","author":"JM Taube","year":"2014","unstructured":"Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-3271.","journal-title":"Clin Cancer Res"},{"issue":"31","key":"1234_CR17","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond M, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2013;31(31):3997. https:\/\/doi.org\/10.1200\/JCO.2013.50.9984.","journal-title":"Arch Pathol Lab Med"},{"issue":"8","key":"1234_CR18","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Winer EP, Coates AS, et al. Strategies for subtypes\u2014dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast Cancer 2011. Ann Oncol. 2011;22(8):1736\u201347. https:\/\/doi.org\/10.1093\/annonc\/mdr304.","journal-title":"Ann Oncol"},{"issue":"3","key":"1234_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"1234_CR20","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1002\/cam4.538","volume":"4","author":"V Vedham","year":"2015","unstructured":"Vedham V, Verma M, Mahabir S. Early-life exposures to infectious agents and later cancer development. Cancer Med. 2015;4(12):1908\u201322. https:\/\/doi.org\/10.1002\/cam4.538.","journal-title":"Cancer Med"},{"issue":"3","key":"1234_CR21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/s1074-7613(00)80622-6","volume":"9","author":"GJ Babcock","year":"1998","unstructured":"Babcock GJ, Decker LL, Volk M, et al. EBV persistence in memory B cells in vivo. Immunity. 1998;9(3):395\u2013404. https:\/\/doi.org\/10.1016\/s1074-7613(00)80622-6.","journal-title":"Immunity"},{"issue":"4","key":"1234_CR22","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3390\/microorganisms9040778","volume":"9","author":"T Murata","year":"2021","unstructured":"Murata T. Human Herpesvirus and the immune checkpoint PD-1\/PD-L1 pathway: disorders and strategies for survival. Microorganisms. 2021;9(4):778. https:\/\/doi.org\/10.3390\/microorganisms9040778.","journal-title":"Microorganisms"},{"issue":"3","key":"1234_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s12253-010-9325-z","volume":"17","author":"M Kadivar","year":"2011","unstructured":"Kadivar M, Monabati A, Joulaee A, et al. Epstein-Barr virus and breast cancer: lack of evidence for an association in Iranian women. Pathol Oncol Res. 2011;17(3):489\u201392. https:\/\/doi.org\/10.1007\/s12253-010-9325-z.","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"1234_CR24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13104-019-4178-3","volume":"12","author":"R Dowran","year":"2019","unstructured":"Dowran R, Joharinia N, Safaei A, et al. No detection of EBV, BKV and JCV in breast cancer tissue samples in Iran. BMC Res Notes. 2019;12(1):171. https:\/\/doi.org\/10.1186\/s13104-019-4178-3.","journal-title":"BMC Res Notes"},{"issue":"2","key":"1234_CR25","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000502131","volume":"29","author":"Q Jin","year":"2020","unstructured":"Jin Q, Su J, Yan D, et al. Epstein-Barr virus infection and increased sporadic breast carcinoma risk: a Meta-analysis. Med Princ Pract. 2020;29(2):195\u2013200. https:\/\/doi.org\/10.1159\/000502131.","journal-title":"Med Princ Pract"},{"key":"1234_CR26","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.2147\/idr.S313219","volume":"14","author":"SA Metwally","year":"2021","unstructured":"Metwally SA, Abo-Shadi MA, Abdel Fattah NF, et al. Presence of HPV, EBV and HMTV viruses among Egyptian breast Cancer women: molecular detection and clinical relevance. Infect Drug Resist. 2021;14:2327\u201339. https:\/\/doi.org\/10.2147\/idr.S313219.","journal-title":"Infect Drug Resist"},{"issue":"9","key":"1234_CR27","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1097\/00130404-200305000-00010","volume":"63","author":"PG Murray","year":"2003","unstructured":"Murray PG, Lissauer D, Junying J, et al. Reactivity with a monoclonal antibody to Epstein-Barr virus (EBV) nuclear antigen 1 defines a subset of aggressive breast cancers in the absence of the EBV genome. Cancer Res. 2003;63(9):2338\u201343. https:\/\/doi.org\/10.1097\/00130404-200305000-00010.","journal-title":"Cancer Res"},{"issue":"24","key":"1234_CR28","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.2217\/fon-2019-0232","volume":"15","author":"M Farahmand","year":"2019","unstructured":"Farahmand M, Monavari SH, Shoja Z, et al. Epstein-Barr virus and risk of breast cancer: a systematic review and meta-analysis. Future Oncol. 2019;15(24):2873\u201385. https:\/\/doi.org\/10.2217\/fon-2019-0232.","journal-title":"Future Oncol"},{"issue":"28","key":"1234_CR29","doi-asserted-by":"publisher","first-page":"99","DOI":"10.14163\/j.cnki.11-5547\/r.2020.28.044","volume":"15","author":"YLS Duan","year":"2020","unstructured":"Duan YLS, Hb J. Correlation analysis between EB virus infection and BI-RADS grading. China Pract Med. 2020;15(28):99\u2013100. https:\/\/doi.org\/10.14163\/j.cnki.11-5547\/r.2020.28.044.","journal-title":"China Pract Med"},{"issue":"6","key":"1234_CR30","doi-asserted-by":"publisher","first-page":"e99857","DOI":"10.1371\/journal.pone.0099857","volume":"9","author":"G Xiong","year":"2014","unstructured":"Xiong G, Zhang B, Huang MY, et al. Epstein-Barr virus (EBV) infection in Chinese children: a retrospective study of age-specific prevalence. PLoS One. 2014;9(6):e99857. https:\/\/doi.org\/10.1371\/journal.pone.0099857.","journal-title":"PLoS One"},{"issue":"3","key":"1234_CR31","doi-asserted-by":"publisher","first-page":"e0193171","DOI":"10.1371\/journal.pone.0193171","volume":"13","author":"J Cui","year":"2018","unstructured":"Cui J, Yan W, Xu S, et al. Anti-Epstein-Barr virus antibodies in Beijing during 2013-2017: what we have found in the different patients. PLoS One. 2018;13(3):e0193171. https:\/\/doi.org\/10.1371\/journal.pone.0193171.","journal-title":"PLoS One"},{"issue":"1","key":"1234_CR32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.16150\/j.1671-2870.2020.01.015","volume":"19","author":"BY Hu Ying","year":"2020","unstructured":"Hu Ying BY, Bai J, Lu Y-P, Cheng G-Z, Guo Y-J, Jie X. Analysis of clinical and laboratory characteristics of EB virus infection in 67 adult patients. J Diagn Concepts Pract. 2020;19(1):74\u20139. https:\/\/doi.org\/10.16150\/j.1671-2870.2020.01.015.","journal-title":"J Diagn Concepts Pract"},{"issue":"2","key":"1234_CR33","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/sj.bjc.6606048","volume":"104","author":"C Mazouni","year":"2011","unstructured":"Mazouni C, Fina F, Romain S, et al. Epstein-Barr virus as a marker of biological aggressiveness in breast cancer. Br J Cancer. 2011;104(2):332\u20137. https:\/\/doi.org\/10.1038\/sj.bjc.6606048.","journal-title":"Br J Cancer"},{"issue":"2","key":"1234_CR34","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jnci.2017.02.002","volume":"29","author":"NEH El-Naby","year":"2017","unstructured":"El-Naby NEH, Hassan Mohamed H, Mohamed Goda A, et al. Epstein-Barr virus infection and breast invasive ductal carcinoma in Egyptian women: a single center experience. J Egypt Natl Canc Inst. 2017;29(2):77\u201382. https:\/\/doi.org\/10.1016\/j.jnci.2017.02.002.","journal-title":"J Egypt Natl Canc Inst"},{"issue":"1","key":"1234_CR35","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12935-021-02009-4","volume":"21","author":"K Nagi","year":"2021","unstructured":"Nagi K, Gupta I, Jurdi N, et al. High-risk human papillomaviruses and Epstein-Barr virus in breast cancer in Lebanese women and their association with tumor grade: a molecular and tissue microarray study. Cancer Cell Int. 2021;21(1):308. https:\/\/doi.org\/10.1186\/s12935-021-02009-4.","journal-title":"Cancer Cell Int"},{"issue":"11","key":"1234_CR36","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1128\/jvi.00076-07","volume":"81","author":"JH Lin","year":"2007","unstructured":"Lin JH, Tsai CH, Chu JS, et al. Dysregulation of HER2\/HER3 signaling axis in Epstein-Barr virus-infected breast carcinoma cells. J Virol. 2007;81(11):5705\u201313. https:\/\/doi.org\/10.1128\/jvi.00076-07.","journal-title":"J Virol"},{"key":"1234_CR37","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ebiom.2016.05.025","volume":"9","author":"H Hu","year":"2016","unstructured":"Hu H, Luo ML, Desmedt C, et al. Epstein-Barr virus infection of mammary epithelial cells promotes malignant transformation. EBioMedicine. 2016;9:148\u201360. https:\/\/doi.org\/10.1016\/j.ebiom.2016.05.025.","journal-title":"EBioMedicine"},{"key":"1234_CR38","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3389\/fonc.2018.00316","volume":"8","author":"MOE Abdallah","year":"2018","unstructured":"Abdallah MOE, Algizouli UK, Suliman MA, et al. EBV associated breast Cancer whole Methylome analysis reveals viral and developmental enriched pathways. Front Oncol. 2018;8:316. https:\/\/doi.org\/10.3389\/fonc.2018.00316.","journal-title":"Front Oncol"},{"key":"1234_CR39","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3389\/fonc.2018.00111","volume":"8","author":"FS Cyprian","year":"2018","unstructured":"Cyprian FS, Al-Farsi HF, Vranic S, et al. Epstein-Barr virus and human papillomaviruses interactions and their roles in the initiation of epithelial-Mesenchymal transition and Cancer progression. Front Oncol. 2018;8:111. https:\/\/doi.org\/10.3389\/fonc.2018.00111.","journal-title":"Front Oncol"},{"issue":"1","key":"1234_CR40","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00432-006-0141-5","volume":"133","author":"JH Tsai","year":"2007","unstructured":"Tsai JH, Hsu CS, Tsai CH, et al. Relationship between viral factors, axillary lymph node status and survival in breast cancer. J Cancer Res Clin Oncol. 2007;133(1):13\u201321. https:\/\/doi.org\/10.1007\/s00432-006-0141-5.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"127","key":"1234_CR41","doi-asserted-by":"publisher","first-page":"127ra37","DOI":"10.1126\/scitranslmed.3003689","volume":"4","author":"JM Taube","year":"2012","unstructured":"Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med. 2012;4(127):127ra37. https:\/\/doi.org\/10.1126\/scitranslmed.3003689.","journal-title":"Sci Transl Med"},{"key":"1234_CR42","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1200\/JCO.2017.35.15_suppl.506","volume":"35","author":"R Nanda","year":"2017","unstructured":"Nanda R, Liu M, Yau C, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2. J Clin Oncol. 2017;35:506. https:\/\/doi.org\/10.1200\/JCO.2017.35.15_suppl.506.","journal-title":"J Clin Oncol"},{"key":"1234_CR43","doi-asserted-by":"publisher","first-page":"x25","DOI":"10.1093\/annonc\/mdx656","volume":"28","author":"J Cortes Castan","year":"2017","unstructured":"Cortes Castan J, Guo Z, Karantza V, et al. 89TiP - KEYNOTE-355: randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC). Ann Oncol. 2017;28:x25. https:\/\/doi.org\/10.1093\/annonc\/mdx656.","journal-title":"Ann Oncol"},{"issue":"23","key":"1234_CR44","doi-asserted-by":"publisher","first-page":"12189","DOI":"10.18632\/oncotarget.2608","volume":"5","author":"W Fang","year":"2014","unstructured":"Fang W, Zhang J, Hong S, et al. EBV-driven LMP1 and IFN-\u03b3 up-regulate PD-L1 in nasopharyngeal carcinoma: implications for oncotargeted therapy. Oncotarget. 2014;5(23):12189\u2013202. https:\/\/doi.org\/10.18632\/oncotarget.2608.","journal-title":"Oncotarget"},{"key":"1234_CR45","doi-asserted-by":"publisher","unstructured":"Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513(7517):202\u20139. https:\/\/doi.org\/10.1038\/nature13480.","DOI":"10.1038\/nature13480"},{"issue":"1","key":"1234_CR46","doi-asserted-by":"publisher","first-page":"17810","DOI":"10.1038\/s41598-017-18132-0","volume":"7","author":"JW Moon","year":"2017","unstructured":"Moon JW, Kong SK, Kim BS, et al. IFN\u03b3 induces PD-L1 overexpression by JAK2\/STAT1\/IRF-1 signaling in EBV-positive gastric carcinoma. Sci Rep. 2017;7(1):17810. https:\/\/doi.org\/10.1038\/s41598-017-18132-0.","journal-title":"Sci Rep"},{"issue":"4","key":"1234_CR47","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252\u201364. https:\/\/doi.org\/10.1038\/nrc3239.","journal-title":"Nat Rev Cancer"},{"issue":"19","key":"1234_CR48","doi-asserted-by":"publisher","first-page":"31347","DOI":"10.18632\/oncotarget.15532","volume":"8","author":"M Zhang","year":"2017","unstructured":"Zhang M, Sun H, Zhao S, et al. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. Oncotarget. 2017;8(19):31347\u201354. https:\/\/doi.org\/10.18632\/oncotarget.15532.","journal-title":"Oncotarget"},{"issue":"3","key":"1234_CR49","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.bulcan.2017.11.012","volume":"105","author":"A Monneur","year":"2018","unstructured":"Monneur A, Gon\u00e7alves A, Bertucci F. PD-L1 expression and PD-1\/PD-L1 inhibitors in breast cancer. Bull Cancer. 2018;105(3):263\u201374. https:\/\/doi.org\/10.1016\/j.bulcan.2017.11.012.","journal-title":"Bull Cancer"},{"issue":"2","key":"1234_CR50","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/pas.0000000000001173","volume":"43","author":"YC Yeh","year":"2019","unstructured":"Yeh YC, Kao HL, Lee KL, et al. Epstein-Barr virus-associated pulmonary carcinoma: proposing an alternative term and expanding the histologic Spectrum of Lymphoepithelioma-like carcinoma of the lung. Am J Surg Pathol. 2019;43(2):211\u20139. https:\/\/doi.org\/10.1097\/pas.0000000000001173.","journal-title":"Am J Surg Pathol"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-022-01234-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-022-01234-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-022-01234-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T06:06:41Z","timestamp":1657951601000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-022-01234-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,16]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1234"],"URL":"https:\/\/doi.org\/10.1186\/s13000-022-01234-3","relation":{},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,16]]},"assertion":[{"value":"26 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study and protocols were approved by The First Affiliated Hospital of Anhui Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}